An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)

Cited by papers we hold 3

• Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors · 2022
  No notice
• Predictive biomarkers of colon cancer immunotherapy: Present and future · 2022
  No notice
• Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency · 2022
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.